Prostate cancer (mCRPC)
Radioligands, T-cell engagers, and next-gen hormone/PARP combinations in metastatic castration-resistant disease.
Lenses
EarlierApproval →
AZNApprovedcash ok
2026-11-22 (36d)Company-guided
Capivasertib / AKT path prostate adjacency · NCT04399811 · Prostate / hormone combo update
EXELApprovedcash ok
2026-12-02 (46d)Company-guided
Cabometyx solid tumor / prostate combos · NCT04446117 · Prostate combo readout
PFEApprovedcash ok
2026-09-30 (-17d)Estimated
Talazoparib PARP prostate · NCT03395197 · mCRPC franchise update
JANXPh1cash ok
2026-10-28 (11d)Company-guided
JANX007 PSMA TRACTr · NCT05519449 · JANX007 prostate update